OpenLegislation

Division 3.3 Specific requirements for somatic cell therapy medicinal products and tissue engineered productsF1F2

United Kingdom

Original text. Later amendments are not shown.

  1. 3.3.1Introduction: finished product, active substance and starting materials
  2. 3.3.2Specific requirements

Annotations

Textual amendments

F1

Substituted by Commission directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use (Text with EEA relevance).

F2

Substituted by Commission Directive 2009/120/EC of 14 September 2009 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use as regards advanced therapy medicinal products (Text with EEA relevance).